Company / Current Assets
ENANTA PHARMACEUTICALS INC Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$204.3M
FY2025
5-year range
$204.3M / $422.8M
FY2021-FY2025
Trend
-31.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 10 years, ranging from $204M in FY2025 to $437M in FY2020.
Based on SEC 10-K filings.
$204M in FY2025 with a 5-year CAGR of -14.1%.
Declined from $423M to $204M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -13.1%
- 5-Year CAGR
- -14.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.1%, indicating a declining trend.
- In FY2025, current assets decreased 31.9% year-over-year.
- Peak current assets was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $204.3M | -31.9% |
| FY2024 | $299.9M | -29.1% |
| FY2023 | $422.8M | +35.6% |
| FY2022 | $311.7M | -2.3% |
| FY2021 | $319.0M | -27.0% |
| FY2020 | $436.8M | +8.7% |
| FY2019 | $401.8M | +5.6% |
| FY2018 | $380.4M | +59.9% |
| FY2017 | $237.8M | +2.4% |
| FY2016 | $232.2M | +36.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026